Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Other Accumulated Expenses (2019 - 2022)

C4 Therapeutics' Other Accumulated Expenses history spans 4 years, with the latest figure at $309000.0 for Q1 2022.

  • For Q1 2022, Other Accumulated Expenses fell 65.16% year-over-year to $309000.0; the TTM value through Mar 2022 reached $309000.0, down 65.16%, while the annual FY2021 figure was $413000.0, 11.94% down from the prior year.
  • Other Accumulated Expenses reached $309000.0 in Q1 2022 per CCCC's latest filing, down from $413000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $887000.0 in Q1 2021 to a low of $164000.0 in Q3 2020.
  • Average Other Accumulated Expenses over 4 years is $370750.0, with a median of $294500.0 recorded in 2019.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 67.5% in 2020, then tumbled 65.16% in 2022.
  • A 4-year view of Other Accumulated Expenses shows it stood at $280000.0 in 2019, then surged by 67.5% to $469000.0 in 2020, then fell by 11.94% to $413000.0 in 2021, then dropped by 25.18% to $309000.0 in 2022.
  • Per Business Quant, the three most recent readings for CCCC's Other Accumulated Expenses are $309000.0 (Q1 2022), $413000.0 (Q4 2021), and $201000.0 (Q3 2021).